CL2013001296A1 - Inhibidor de fmo3, inhibidor de frk, modulador de lpar3, inhibidor de pde4d, inhibidor de camk1d, nicotinamida, roscovitina, remofovir, acetazolamida y luteolina, entre otros compuestos, para su uso en el tratamiento del dolor, tal como dolor cronico, agudo, dolor neuropatico, dolor inflamatorio y dolor artritico. - Google Patents
Inhibidor de fmo3, inhibidor de frk, modulador de lpar3, inhibidor de pde4d, inhibidor de camk1d, nicotinamida, roscovitina, remofovir, acetazolamida y luteolina, entre otros compuestos, para su uso en el tratamiento del dolor, tal como dolor cronico, agudo, dolor neuropatico, dolor inflamatorio y dolor artritico.Info
- Publication number
- CL2013001296A1 CL2013001296A1 CL2013001296A CL2013001296A CL2013001296A1 CL 2013001296 A1 CL2013001296 A1 CL 2013001296A1 CL 2013001296 A CL2013001296 A CL 2013001296A CL 2013001296 A CL2013001296 A CL 2013001296A CL 2013001296 A1 CL2013001296 A1 CL 2013001296A1
- Authority
- CL
- Chile
- Prior art keywords
- pain
- inhibitor
- remofovir
- lpar3
- camk1d
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 4
- 208000002193 Pain Diseases 0.000 title 3
- GWNHAOBXDGOXRR-HJFSHJIFSA-N 9-[2-[[(2r,4s)-4-(3-chlorophenyl)-2-oxo-1,3,2$l^{5}-dioxaphosphinan-2-yl]methoxy]ethyl]purin-6-amine Chemical compound C1([C@@H]2CCO[P@](O2)(=O)COCCN2C=3N=CN=C(C=3N=C2)N)=CC=CC(Cl)=C1 GWNHAOBXDGOXRR-HJFSHJIFSA-N 0.000 title 1
- 101150021564 FMO3 gene Proteins 0.000 title 1
- 206010065390 Inflammatory pain Diseases 0.000 title 1
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 title 1
- BZKPWHYZMXOIDC-UHFFFAOYSA-N acetazolamide Chemical compound CC(=O)NC1=NN=C(S(N)(=O)=O)S1 BZKPWHYZMXOIDC-UHFFFAOYSA-N 0.000 title 1
- 229960000571 acetazolamide Drugs 0.000 title 1
- 208000005298 acute pain Diseases 0.000 title 1
- 230000002917 arthritic effect Effects 0.000 title 1
- 230000001684 chronic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 title 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 title 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 title 1
- 235000009498 luteolin Nutrition 0.000 title 1
- 208000004296 neuralgia Diseases 0.000 title 1
- 208000021722 neuropathic pain Diseases 0.000 title 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10190922 | 2010-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2013001296A1 true CL2013001296A1 (es) | 2014-04-25 |
Family
ID=44936283
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2013001296A CL2013001296A1 (es) | 2010-11-11 | 2013-05-10 | Inhibidor de fmo3, inhibidor de frk, modulador de lpar3, inhibidor de pde4d, inhibidor de camk1d, nicotinamida, roscovitina, remofovir, acetazolamida y luteolina, entre otros compuestos, para su uso en el tratamiento del dolor, tal como dolor cronico, agudo, dolor neuropatico, dolor inflamatorio y dolor artritico. |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20130252924A1 (es) |
| EP (2) | EP2674161A1 (es) |
| JP (1) | JP2013542242A (es) |
| KR (1) | KR20140009244A (es) |
| CN (1) | CN103415286A (es) |
| AU (1) | AU2011328009A1 (es) |
| BR (1) | BR112013011874A2 (es) |
| CA (1) | CA2817290A1 (es) |
| CL (1) | CL2013001296A1 (es) |
| EA (1) | EA201300558A1 (es) |
| IL (1) | IL226307A0 (es) |
| MX (1) | MX2013005361A (es) |
| SG (1) | SG190224A1 (es) |
| WO (1) | WO2012062925A2 (es) |
| ZA (1) | ZA201303605B (es) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013156232A1 (en) * | 2012-04-16 | 2013-10-24 | Algiax Pharmaceuticals Gmbh | Use of benzofuranylsulfonates in neuropathic pain |
| AU2013257951A1 (en) * | 2012-05-11 | 2015-01-22 | Akron Molecules Ag | Use of compounds for the treatment of pain |
| TW201410244A (zh) * | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療ｇａｂａ媒介之疾病之拉喹莫德（ｌａｑｕｉｎｉｍｏｄ） |
| CN104602690A (zh) * | 2012-08-29 | 2015-05-06 | 默克专利股份有限公司 | 用于治疗骨关节炎的ddr2抑制剂 |
| KR101540739B1 (ko) | 2013-09-02 | 2015-08-05 | 가톨릭대학교 산학협력단 | 펠리티닙을 포함하는 톡소포자충 감염증의 예방 및 치료용 조성물 |
| US20150133547A1 (en) * | 2013-11-08 | 2015-05-14 | Richard W. Hertle | Method and composition for treating glaucoma |
| US9095505B2 (en) | 2013-11-08 | 2015-08-04 | Rbg Group, Ltd. | Pyrethroids for treatment of ocular movement disorders |
| CN106456599B (zh) * | 2013-12-12 | 2019-05-14 | 比皮艾思药物研发有限公司 | 用于治疗或减轻疼痛的氨基磺酸酯衍生化合物 |
| WO2015088271A1 (en) | 2013-12-12 | 2015-06-18 | Bio-Pharm Solutions, Co., Ltd. | Sulfamate derivative compound for use in preventing or treating epilepsy |
| CN105979942B (zh) * | 2013-12-12 | 2018-12-07 | 比皮艾思药物研发有限公司 | 用于治疗或缓解疼痛的氨基磺酸酯衍生物 |
| US20170136020A1 (en) * | 2014-06-11 | 2017-05-18 | Antecip Bioventures Ii Llc | Compositions comprising dasatinib for treating complex regional pain syndrome |
| US9745308B2 (en) * | 2014-09-12 | 2017-08-29 | Chiesi Farmaceutici S.P.A. | Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors |
| CN104447913B (zh) * | 2014-11-06 | 2017-05-31 | 四川大学 | 功能化淫羊藿苷衍生物及其制备方法与应用 |
| KR101850607B1 (ko) * | 2015-07-23 | 2018-04-19 | 서울대학교산학협력단 | 인돌리지노[3,2-ｃ]퀴놀린계 형광 프로브 |
| CN105168201B (zh) * | 2015-09-30 | 2017-11-07 | 南通大学 | 牡荆素在制备治疗术后疼痛药物中的应用 |
| US9937146B2 (en) | 2016-03-23 | 2018-04-10 | Bioadatp, Llc | Enkephalin-influencing composition and method |
| KR102421013B1 (ko) * | 2016-05-19 | 2022-07-14 | 에스케이바이오팜 주식회사 | 삼차신경통을 예방 또는 치료하기 위한 카바메이트 화합물의 용도 |
| US20190321493A1 (en) * | 2016-11-18 | 2019-10-24 | Mayo Foundation For Medical Education And Research | Materials and methods for treating regional pain |
| US11396516B2 (en) | 2017-06-16 | 2022-07-26 | The General Hospital Corporation | Tricyclic compounds as Cyp1 inhibitors |
| CN109722389B (zh) * | 2017-10-31 | 2021-05-14 | 鲁南新时代生物技术有限公司 | 一种烟曲霉菌液体培养基 |
| CN107721902A (zh) * | 2017-11-08 | 2018-02-23 | 中国科学院上海药物研究所 | 阿普斯特与烟酰胺的共结晶及其制备方法和应用 |
| US11103465B2 (en) | 2017-11-22 | 2021-08-31 | Ted's Brain Science, Inc. | Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof |
| US20200399250A1 (en) * | 2017-11-23 | 2020-12-24 | Biomed X Gmbh | Pyrimidine Derivatives as Tropomyosin Receptor Kinase A (TRKA) Inhibitors |
| CN108354943A (zh) * | 2018-02-13 | 2018-08-03 | 南方医科大学南方医院 | 新生霉素用于制备抑制trpv1表达和转运功能的药物的用途 |
| CN108416164B (zh) * | 2018-03-23 | 2021-09-28 | 南京大学 | 基于有限数目温度传感器的三维片上网络温度重建系统 |
| CN109172586B (zh) * | 2018-07-06 | 2021-01-19 | 福州百草堂医药科技有限公司 | 一种用于缓解皮肤刺激的组合物 |
| GB201818750D0 (en) * | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
| CN113490739A (zh) * | 2019-01-23 | 2021-10-08 | 通路治疗公司 | 通过磷酸二酯酶4(pde4)抑制治疗癫痫的方法 |
| CN109929808B (zh) * | 2019-04-02 | 2020-10-16 | 中国医学科学院医药生物技术研究所 | 以line-1 orf1蛋白为靶点的抗癌药物筛选模型及筛选方法 |
| CN110200980B (zh) * | 2019-05-13 | 2022-07-12 | 华南师范大学 | 一种荷载青蒿素的柑橘果胶的口服纳米粒子 |
| CN109985040A (zh) * | 2019-05-15 | 2019-07-09 | 南京正大天晴制药有限公司 | 一种用于超前镇痛的注射用帕瑞昔布钠药用组合物及其制备方法 |
| CN110308219A (zh) * | 2019-06-17 | 2019-10-08 | 天津市天大赛达协同创新科技研究院有限公司 | 一种测定反应液中4，4-偶氮吡啶和丙璜舒含量的方法 |
| CN112322592B (zh) * | 2019-08-05 | 2021-12-28 | 中国科学院天津工业生物技术研究所 | 一种参与紫草素生物合成的cyp76b100蛋白及其编码基因与应用 |
| CN110507670B (zh) * | 2019-09-24 | 2023-04-07 | 江西天元药业有限公司 | 精制熊胆粉及预防治疗肝病肝纤维化改善肝功能的用途 |
| CN110693873B (zh) * | 2019-10-28 | 2022-07-12 | 杭州市西溪医院 | 冬凌草活性成分组合物的制备及应用 |
| CN110714047B (zh) * | 2019-11-19 | 2022-10-28 | 湖南新合新生物医药有限公司 | 一种甾体中间体1,2位脱氢的方法 |
| US20210155597A1 (en) * | 2019-11-21 | 2021-05-27 | Synventa Llc | Compositions and methods for treatment of pain |
| CN110964043B (zh) * | 2019-12-02 | 2022-05-24 | 广州中医药大学(广州中医药研究院) | 一种瓜氨酸探针化合物及其应用 |
| CN111122740B (zh) * | 2019-12-31 | 2022-06-14 | 辰欣药业股份有限公司 | 一种基于c18键合相色谱柱分离测定奥沙利铂有关物质的方法 |
| CN113491793A (zh) * | 2020-03-18 | 2021-10-12 | 中国科学院上海硅酸盐研究所 | 一种线结构复合物及其制备方法和应用 |
| US11253534B2 (en) | 2020-03-23 | 2022-02-22 | Sabine Hazan | Method of preventing COVID-19 infection |
| US11744866B2 (en) | 2020-03-18 | 2023-09-05 | Sabine Hazan | Methods of preventing and treating COVID-19 infection with probiotics |
| US11278520B2 (en) | 2020-03-31 | 2022-03-22 | Sabine Hazan | Method of preventing COVID-19 infection |
| CN111617092A (zh) * | 2020-04-20 | 2020-09-04 | 牡丹江医学院 | 一种用于治疗肺癌的药物及其制备方法 |
| WO2022031607A1 (en) * | 2020-08-02 | 2022-02-10 | Powderpost Llc | Apothecarial compositions and related methods of treatment |
| CN114159450B (zh) * | 2020-09-10 | 2023-10-27 | 上海交通大学 | 原人参二醇类化合物在治疗疼痛和成瘾物质躯体依赖、精神依赖和成瘾的用途 |
| CN112546056B (zh) * | 2020-12-11 | 2022-02-25 | 南京医科大学 | 一种用于治疗化疗诱发的外周神经病变的组合物及其应用 |
| CN112526038B (zh) * | 2020-12-15 | 2022-07-12 | 河北科技大学 | 一种卡洛芬及其有关物质的检测方法 |
| CN112687803B (zh) * | 2020-12-23 | 2022-10-04 | 西南大学 | 二羟丙茶碱在倒置钙钛矿太阳能电池中的应用及器件的制备方法 |
| CN112903868B (zh) * | 2021-02-04 | 2022-06-28 | 中山市中医院 | 一种复方番石榴制剂中多种化学成分的含量测定方法 |
| CN113063888A (zh) * | 2021-03-26 | 2021-07-02 | 海南海力制药有限公司 | 一种阿奇霉素片杂质的检测方法及一致性评价方法 |
| CN115372487B (zh) * | 2021-05-18 | 2023-10-10 | 成都倍特得诺药业有限公司 | 盐酸格拉司琼中杂质e的hplc测定方法 |
| CN113496309B (zh) * | 2021-06-15 | 2024-04-19 | 中国食品药品检定研究院 | 西洋参生长年限预测方法、模型的训练方法及装置 |
| CN113533598B (zh) * | 2021-07-30 | 2023-03-24 | 海南葫芦娃药业集团股份有限公司 | 一种小儿肺热咳喘颗粒中黄芩含量的高效液相色谱分析方法 |
| CN113616649B (zh) * | 2021-09-10 | 2022-12-09 | 四川大学华西医院 | 一种治疗肝癌的联合用药物 |
| CN113984726B (zh) * | 2021-10-20 | 2024-02-02 | 上海大学 | 一种氨基苯硼酸功能化磁珠/乙二醛修饰dna检测汞离子的方法 |
| CN114217071B (zh) * | 2021-12-01 | 2023-11-14 | 柏荣诊断产品（上海）有限公司 | 一种高特异性透散射一体法铁蛋白胶乳比浊检测试剂盒 |
| CN114159425A (zh) * | 2021-12-21 | 2022-03-11 | 宁夏医科大学 | 川陈皮素在制备治疗神经病理性疼痛药物中的用途 |
| CN114591214B (zh) * | 2022-03-25 | 2023-06-02 | 北京大学深圳医院 | 靛红衍生物及其制备方法 |
| CN115010628A (zh) * | 2022-06-30 | 2022-09-06 | 武汉理工大学 | 一种n-芳基氨基甲酸酯类化合物、其制备方法及应用 |
| CN115044274B (zh) * | 2022-07-19 | 2023-04-28 | 宁波科鑫腐蚀控制工程有限公司 | 一种陶瓷颗粒改性纤维环氧复合涂层及其制备方法和应用 |
| CN115124511B (zh) * | 2022-07-28 | 2023-09-26 | 中国人民解放军北部战区总医院 | 他克林衍生物及其制备方法与作为cdk2/9抑制剂的应用 |
| CN116407557A (zh) * | 2023-05-29 | 2023-07-11 | 四川大学华西医院 | 一种防治出血性脑卒中的药物组合物及其应用 |
| CN116585298A (zh) * | 2023-06-30 | 2023-08-15 | 江苏海洋大学 | 一种偶联药物及其组合物和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003229392A1 (en) * | 2002-05-31 | 2003-12-19 | Scegen Pty Ltd | Self-coalescing or self-aggregating proteins derived from a membrane translocating sequence |
| ES2378374T3 (es) * | 2003-11-20 | 2012-04-11 | Astellas Pharma Inc. | Inhibidores de la PDE 4 para el tratamiento de la cistitis intersticial |
| US20050222169A1 (en) * | 2004-01-16 | 2005-10-06 | Nawaz Ahmad | Compositions and methods of treating infections |
| CN1319520C (zh) * | 2005-02-03 | 2007-06-06 | 上海交通大学 | 核苷膦酸类化合物的脂质体和脂质复合物制剂 |
| US20130029989A1 (en) * | 2010-04-15 | 2013-01-31 | The Royal Institution For The Advancement Of Learning/Mcgill University | Topical treatments for pain |
| US20130065936A1 (en) * | 2010-05-14 | 2013-03-14 | The Regents Of The University Of California | Modulation of bioactive epoxy-fatty acid levels by phosphodiesterase inhibitors |
-
2011
- 2011-11-11 WO PCT/EP2011/069986 patent/WO2012062925A2/en active Application Filing
- 2011-11-11 CN CN2011800646314A patent/CN103415286A/zh active Pending
- 2011-11-11 EP EP13174939.2A patent/EP2674161A1/en not_active Withdrawn
- 2011-11-11 KR KR1020137014995A patent/KR20140009244A/ko not_active Application Discontinuation
- 2011-11-11 EP EP11781808.8A patent/EP2637649B1/en active Active
- 2011-11-11 EA EA201300558A patent/EA201300558A1/ru unknown
- 2011-11-11 JP JP2013538217A patent/JP2013542242A/ja not_active Withdrawn
- 2011-11-11 CA CA2817290A patent/CA2817290A1/en not_active Abandoned
- 2011-11-11 AU AU2011328009A patent/AU2011328009A1/en not_active Abandoned
- 2011-11-11 BR BR112013011874A patent/BR112013011874A2/pt not_active IP Right Cessation
- 2011-11-11 US US13/884,920 patent/US20130252924A1/en not_active Abandoned
- 2011-11-11 MX MX2013005361A patent/MX2013005361A/es not_active Application Discontinuation
- 2011-11-11 SG SG2013035795A patent/SG190224A1/en unknown
-
2013
- 2013-05-10 CL CL2013001296A patent/CL2013001296A1/es unknown
- 2013-05-12 IL IL226307A patent/IL226307A0/en unknown
- 2013-05-17 ZA ZA2013/03605A patent/ZA201303605B/en unknown
-
2014
- 2014-05-08 US US14/273,081 patent/US20140349969A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20140349969A1 (en) | 2014-11-27 |
| MX2013005361A (es) | 2013-10-25 |
| EA201300558A1 (ru) | 2013-11-29 |
| IL226307A0 (en) | 2013-07-31 |
| AU2011328009A1 (en) | 2013-05-30 |
| SG190224A1 (en) | 2013-06-28 |
| CN103415286A (zh) | 2013-11-27 |
| BR112013011874A2 (pt) | 2019-09-24 |
| JP2013542242A (ja) | 2013-11-21 |
| EP2674161A1 (en) | 2013-12-18 |
| KR20140009244A (ko) | 2014-01-22 |
| EP2637649B1 (en) | 2014-12-24 |
| WO2012062925A2 (en) | 2012-05-18 |
| WO2012062925A3 (en) | 2012-07-12 |
| AU2011328009A8 (en) | 2013-08-01 |
| CA2817290A1 (en) | 2012-05-18 |
| US20130252924A1 (en) | 2013-09-26 |
| ZA201303605B (en) | 2014-11-26 |
| EP2637649A2 (en) | 2013-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2013001296A1 (es) | Inhibidor de fmo3, inhibidor de frk, modulador de lpar3, inhibidor de pde4d, inhibidor de camk1d, nicotinamida, roscovitina, remofovir, acetazolamida y luteolina, entre otros compuestos, para su uso en el tratamiento del dolor, tal como dolor cronico, agudo, dolor neuropatico, dolor inflamatorio y dolor artritico. | |
| BR112013018953A2 (pt) | composição efervescente na forma sólida para uso em aplicações vaginais para o tratamento de infecções vaginais. | |
| HK1246296A1 (zh) | 多環氨基甲酰基吡啶酮化合物和其用於治療hiv感染的用途 | |
| IL244995B (en) | A pharmaceutical composition containing a pcsk9 inhibitor in the treatment of hyperlipidemia | |
| HK1246295A1 (zh) | 多環氨基甲酰基吡啶酮化合物和其用於治療hiv感染的用途 | |
| CL2014002087A1 (es) | Composición veterinaria masticable que comprende como agente activo un compuesto derivado de isoxazolina; y su uso para el tratamiento y/o prevención de una infestación y/o infección por parásitos en un animal. | |
| CO6811867A2 (es) | Cannabinoides para uso en el tratamiento del dolor neuropático | |
| BR112012022879A2 (pt) | composto, composição farmacêutica, uso do composto e método de tratamento | |
| CL2014003472A1 (es) | Pro-farmacos derivados de (e)-n-metil-n-((3-metilbenzofuran-2-il)metil)-3-(7-oxo-5,6,7,8-tetrahidro-1,8-naftiridin-3-il)acrilamida; composicion farmaceutica que los comprende; y su uso para tratar una infeccion bacteriana. | |
| DK2957282T3 (en) | Oral antiseptic composition for treating oral mucositis | |
| CL2014003059A1 (es) | Uso de seaprose para eliminar biopelículas bacterianas; composicion de seaprose. | |
| CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
| CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
| MX2014015039A (es) | Inhibidores de fbx03. | |
| CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
| CL2013002193A1 (es) | Uso de un producto que comprende macitentano o una sal del mismo en combinacion con un agente alquilante o un inhibidor mitotico para preparar un medicamento util en el tratamiento de glioma maligno. | |
| CL2014003153A1 (es) | Métodos para hacer complejos de coordinación micelar seguro para el tratamiento de plantas y formulaciones de estos | |
| CL2014000269A1 (es) | Uso de interleucina 7 (il-7) para tratar hepatitis c en combinacion o con posterioridad a un agente antiviral o una combinacion de agentes antivirales. | |
| CL2013001313A1 (es) | Composicion que comprende microorganismos probióticos no replicantes para prevenir o tratar infecciones gastrointestinales | |
| CL2015001003A1 (es) | Uso de clotianidina para reducir o eliminar el piojo de mar en una población de peces. | |
| FR3000491B1 (fr) | Composes utilisables dans le traitement des infections mycobacteriennes | |
| AR078323A1 (es) | Tratamiento con fampridina de liberacion sostenida en pacientes con esclerosis multiple | |
| GB2515440B (en) | Vesicular Formulations for use in the treatment of Rosacea | |
| ITTO20131062A1 (it) | Procedimento per ridurre i danni provocati da organismi dannosi in coltivazioni di mais | |
| CL2013003268A1 (es) | Uso de una composición que comprende secnidazol y un antibiótico macrólido para preparar un medicamento útil en el tratamiento de infecciones dentales. |